Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies

被引:71
作者
Bilanges, B. [1 ]
Stokoe, D. [1 ]
机构
[1] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA
关键词
protein synthesis; tumor suppressor genes; mTOR; targeted therapy;
D O I
10.1038/sj.onc.1210431
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Analysis of the recurrent genetic aberrations present in human tumors provides insight into how normal cells escape appropriate proliferation and survival cues. Commonly mutated genes encode proteins that monitor DNA damage ( e. g., p53), proteins that regulate the cell cycle ( such as Rb), and proteins that regulate signal transduction pathways ( such as APC, PTEN and Ras). Analysis of the relevant targets and downstream events of these genes in normal and tumor cells will clearly highlight important pathways for tumorigenesis. However, more infrequent mutations are also informative in de. ning events critical for the process of tumorigenesis, and often delineate important pathways lying downstream of commonly mutated oncogenes and tumor suppressors. Together, these studies have led to the conclusion that deregulated protein synthesis plays an important role in human cancer. This review will discuss the evidence implicating mRNA translation as an important downstream consequence of signal transduction pathways initiated by mutated oncogenes and tumor suppressors, as well as additional genetic findings implicating the importance of global and specific translational control in human cancer. It will also discuss therapeutic strategies that take advantage of differences in translational regulation between normal and tumor cells.
引用
收藏
页码:5973 / 5990
页数:18
相关论文
共 178 条
[1]   LKB1-dependent signaling pathways [J].
Alessi, Dario R. ;
Sakamoto, Kei ;
Bayascas, Jose R. .
ANNUAL REVIEW OF BIOCHEMISTRY, 2006, 75 :137-163
[2]   Many ribosomal protein genes are cancer genes in zebrafish [J].
Amsterdam, A ;
Sadler, KC ;
Lai, K ;
Farrington, S ;
Bronson, RT ;
Lees, JA ;
Hopkins, N .
PLOS BIOLOGY, 2004, 2 (05) :690-698
[3]   Gene encoding protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer [J].
Anand, N ;
Murthy, S ;
Amann, G ;
Wernick, M ;
Porter, LA ;
Cukier, IH ;
Collins, C ;
Gray, JW ;
Diebold, J ;
Demetrick, DJ ;
Lee, JM .
NATURE GENETICS, 2002, 31 (03) :301-305
[4]   Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells [J].
Avdulov, S ;
Li, S ;
Michalek, V ;
Burrichter, D ;
Peterson, M ;
Perlman, DM ;
Manivel, JC ;
Sonenberg, N ;
Yee, D ;
Bitterman, PB ;
Polunovsky, VA .
CANCER CELL, 2004, 5 (06) :553-563
[5]   Biological response determinants in HSV-tk plus ganciclovir gene therapy for prostate cancer [J].
Ayala, G ;
Satoh, T ;
Li, R ;
Shalev, M ;
Gdor, Y ;
Aguilar-Cordova, E ;
Frolov, A ;
Wheeler, TM ;
Miles, BJ ;
Rauen, K ;
Teh, BS ;
Butler, EB ;
Thompson, TC ;
Kadmon, D .
MOLECULAR THERAPY, 2006, 13 (04) :716-728
[6]   Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway [J].
Bader, AG ;
Feits, KA ;
Jiang, N ;
Chang, HW ;
Vogt, PK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (21) :12384-12389
[7]   Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation [J].
Bader, AG ;
Vogt, PK .
MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (06) :2095-2106
[8]   Defective translational control facilitates vesicular stomatitis virus oncolysis [J].
Balachandran, S ;
Barber, GN .
CANCER CELL, 2004, 5 (01) :51-65
[9]   Vesicular stomatitis virus (VSV) therapy of tumors [J].
Balachandran, S ;
Barber, GN .
IUBMB LIFE, 2000, 50 (02) :135-138
[10]   Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis [J].
Bärlund, M ;
Forozan, F ;
Kononen, J ;
Bubendorf, L ;
Chen, YD ;
Bittner, ML ;
Torhorst, J ;
Haas, P ;
Bucher, C ;
Sauter, G ;
Kallioniemi, OP ;
Kallioniemi, A .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (15) :1252-1259